Job Trends
BioSpace’s 2023 “Best Places to Work,” highlights innovative companies with a positive workplace culture, flexibility and strong leadership.
Labor Market Reports
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second quarter of 2025, with increased pressure from further layoffs.
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.
Now Hiring
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
Looking for a biopharma job in New York? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
Of the 25 companies receiving tax incentives in Massachusetts, 23 will add jobs outside of Boston and Cambridge. Medtronic, which is receiving the largest award, will create 220 roles in Billerica. Other recipients include AbbVie, Dyne Therapeutics and Viridian Therapeutics.
THE LATEST
Kiadis has three compounds in the clinic: K-NK002 in Phase II for HSCT in blood cancer; K-NK003 for relapsed or refractory acute myeloid leukemia (AML); K-NK-ID101 for COVID-19.
It was a particularly busy week for announcements about clinical trials, both related to COVID-19 and everything else. Here’s a look.
THOR-707 is a non-alpha IL-2 candidate that is currently being studied in Phase I trials in solid tumors.
Texas wants to get the word out: It’s not just for oil and pipelines anymore. The Lone Star State is a rapidly emerging biopharma hub, with more than just a lone focus on oncology.
Pfizer indicated yesterday that its Phase III clinical trial of 44,000 volunteers now needs fewer than 2,000 people to be fully enrolled.
Novartis is harnessing the power of Molecular Partners AG’s DARPin platform to develop two therapeutic candidates that could both be used to prevent and treat COVID-19 infection.
Eli Lilly is continuing their other trial in mild-to-moderate COVID-19 patients and stated they “remain confident … that bamlanivimab monotherapy may prevent progression of disease for those earlier in the course of COVID-19.”
Days after the U.S. FDA greenlit the restart of AstraZeneca’s Phase III COVID-19 vaccine trial, the company said the preventative medication boosts immune responses in older and younger adults against the novel coronavirus.
Novartis released promising interim Phase II data of iptacopan in C3 glomerulopathy (C3G). The analysis was presented at the virtual American Society of Nephrology (ASN) 2020 Annual Meeting.
Moderna has fully enrolled its late-stage coronavirus disease 2019 (COVID-19) vaccine trial by hitting its target of 30,000 participants. More than one-third of this cohort includes minority participants.